The new issue of ONCOLife, one of the leading oncology magazines for healthcare professionals, is now available — and it ...

Despite two decades of clinical experience with Everolimus in transplant medicine, cancer patients continue to face ...

START and OneOncology are launching three new early-phase cancer trial sites in California, Texas, and New Jersey, expanding access in community settings where 70% of patients receive care.

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...

ONCOLife presents an exclusive interview with Sarah Hein, CEO of March Biosciences. In this session, we explore clinical ...

Lumipulse G pTau217/β-Amyloid 1-42—for the diagnosis of Alzheimer’s disease. It demonstrated 91.7% sensitivity and 97.3% ...

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...